Approval for pain reliever for osteoarthritic knees to be delayed

Genzyme has to provide FDA with more data on Synvisc-One before the pain-relieving treatment for osteoarthritis can be approved.

Those who were waiting for the approval of Synvisc-One will have to wait a little longer. Genzyme Corp., which is applying for approval of the next generation of Synvisc (hylan G-F 20),